Heart Failure

Results from the DELIVER and DAPA-HF phase 3 trials demonstrate AstraZeneca’s Farxiga’s efficacy in heart failure, regardless of ejection fraction.

How would you handle these patients' questions?

Patients taking the product should consult with their physician or pharmacist to determine whether they have the affected product.

Among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities in the management of the chronic condition.

Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.

Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) tablets are the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death.

A 30-year analysis of more than 110,000 health professionals also suggests that replacing animal products, such as bacon, butter, and cheese, with avocado also reduces cardiovascular events.

Heat waves, which are on the rise, appear to pose particular cardiovascular risk for Black populations and men, new study results show.

It is critical for pharmacists to inquire about the use of e-cigarette or vaping products in patients that present with certain symptoms.

Last month, the FDA approved empagliflozin (Jardiance) to lower the risk of cardiovascular death and hospitalization for heart failure in adult patients.

Ten quiz questions to assess your knowledge on common treatments for heart failure.

Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.

Alteplase (Activase) is indicated for the treatment of acute ischemic stroke, acute myocardial infarction, pulmonary embolism, and blocked central venous catheter.

Empagliflozin demonstrated a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction.

The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.

Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.

American Heart Month is another example of the essential and valuable position that pharmacists hold in improving health care outcomes and optimizing patient-centered care.

Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Association’s Scientific Sessions 2021.

Taking the medication is linked to a 26% increase in new HF diagnosis, results of a study published in ESC Heart Failure show.

These benefits included increased survival, a lower risk of hospital readmission for heart failure, and an overall improvement in quality of life.

Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.

mRNA encoding vascular endothelial growth factor into the myocardium of patients undergoing elective coronary artery bypass surgery was both safe and tolerable in patients with heart failure.

Bacteria, fungi, and other germs that cause endocarditis may enter the bloodstream through improper dental care, catheters, and IV drug use.

If approved, empagliflozin would be the first therapy proven to significantly improve outcomes for individuals with heart failure, according to Boehringer Ingelheim.

But expanding coverage in 2014 was associated with a notable increase in enrollment among individuals with heart failure, study results show.

Empagliflozin demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure, compared with placebo.

Compared to women who followed the Portfolio Diet less frequently, those with the closest alignment were 11% less likely to develop any type of cardiovascular disease, 14% less likely to develop coronary heart disease, and 17% less likely to develop heart failure.

In clinical trials, empagliflozin significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25%.